Mestinon Alternatives Compared
| Mestinon (pyridostigmine) | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|---|
| Mestinon (pyridostigmine) | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Myasthenia Gravis, Dysautonomia, Nerve Agent Pretreatment, Reversal of Nondepolarizing Muscle Relaxants. Mestinon may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Neuromyelitis Optica Spectrum Disorder. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis. Rystiggo may also be used for purposes not listed in this medication guide. |
Related suggestions Myasthenia Gravis
Popular comparisons
|
|||||||||||||||||||||||
| More about Mestinon (pyridostigmine) | More about Ultomiris (ravulizumab) | More about Rystiggo (rozanolixizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Mestinon has an average rating of 6.6 out of 10 from a total of 40 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 25% reported a negative effect. |
Ultomiris has an average rating of 9.6 out of 10 from a total of 7 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Rystiggo has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Mestinon side effects |
View all Ultomiris side effects |
View all Rystiggo side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mestinon prices |
View all Ultomiris prices |
View all Rystiggo prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other pyridostigmine brands include: Mestinon Timespan, Regonol |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
1192.8 hours |
N/A |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 99 drugs are known to interact with Mestinon:
|
A total of 80 drugs are known to interact with Ultomiris:
|
A total of 290 drugs are known to interact with Rystiggo:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 06, 1955 |
December 21, 2018 |
June 26, 2023 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.